...
首页> 外文期刊>Respiratory care >Isoflurane for life-threatening bronchospasm: A 15-year single-center experience
【24h】

Isoflurane for life-threatening bronchospasm: A 15-year single-center experience

机译:异氟醚治疗威胁生命的支气管痉挛:15年的单中心经验

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Children with severe bronchospasm requiring mechanical ventilation may become refractory to conventional therapy. In these critically ill patients, isoflurane is an inhaled anesthetic agent available in some centers to treat bronchospasm. We hypothesized that isoflurane is safe and would lead to improved gas exchange in children with life-threatening bronchospasm refractory to conventional therapy. METHODS: A retrospective review was conducted and included mechanically ventilated children treated with isoflurane in a quaternary pediatric ICU for life-threatening bronchospasm, from 1993 to 2007. Demographic, blood gas, ventilator, and outcome data were collected. RESULTS: Thirty-one patients, with a mean age of 9.5 years (range 0.4-23 years) were treated with isoflurane, from 1993 to 2007. Mean time to initiation of isoflurane after intubation was 13 hours (0-120 h), and the mean maximum isoflurane dose was 1.1% (0.3-2.5%). Mean duration of isoflurane administration was 54.5 hours (range 1-181 h), with a total mean duration of mechanical ventilation of 252 hours (range 16-1,444 h). Isoflurane led to significant improvement in pH and PCO2 within 4 hours of initiation (P ≤.001). Complications during isoflurane administration included hypotension requiring vasoactive infusions in 24 (77%), arrhythmia in 3 (10%), neurologic side effects in 3 (10%), and pneumothorax in 1 (3%) patient. CONCLUSIONS: Isoflurane led to improvement in pH and PCO2 within 4 hours in this series of mechanically ventilated patients with life-threatening bronchospasm. The majority of patients in this series developed hypotension, but there was a low incidence of other side effects related to isoflurane administration. Isoflurane appears to be an effective therapy in patients with life-threatening bronchospasm refractory to conventional therapy. However, further investigation is warranted, given the uncertain overall impact of isoflurane in this context.
机译:背景:需要机械通气的严重支气管痉挛患儿可能对常规治疗无效。在这些重症患者中,异氟烷是一些中心可用于治疗支气管痉挛的吸入麻醉剂。我们假设异氟烷是安全的,并且可以改善传统疗法难治的危及生命的支气管痉挛儿童的气体交换。方法:回顾性研究,包括从1993年至2007年在四级儿科ICU中接受异氟烷治疗的机械通气儿童,以危及生命的支气管痉挛。收集了人口统计学,血气,呼吸机和结局数据。结果:从1993年至2007年,对31名平均年龄为9.5岁(0.4-23岁)的患者进行了异氟烷治疗。插管后开始异氟烷的平均时间为13小时(0-120小时),并且平均最大异氟醚剂量为1.1%(0.3-2.5%)。异氟烷给药的平均持续时间为54.5小时(范围1-181小时),机械通气的总平均持续时间为252小时(范围16-1444小时)。异氟醚在启动后的4小时内导致pH和PCO2的显着改善(P≤.001)。异氟烷给药期间的并发症包括低血压,其中24例(77%)需要血管活性输注,3例(10%)的心律不齐,3例(10%)的神经系统副作用,1例(3%)的气胸。结论:异氟烷可导致这一系列危及生命的支气管痉挛的机械通气患者在4小时内改善pH和PCO2。该系列的大多数患者发生低血压,但与异氟烷给药有关的其他副作用发生率较低。异氟烷似乎是对传统疗法难以治疗的威胁生命的支气管痉挛的有效疗法。但是,鉴于在这种情况下异氟烷的总体影响尚不确定,因此有必要进行进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号